What is Centese?
Centese specializes in innovative surgical drainage solutions, with its flagship product, Thoraguard, designed for cardiothoracic surgery. The Thoraguard system aims to improve patient outcomes by offering precise data monitoring and automated chest tube clearance, thereby addressing common challenges associated with traditional drainage systems. The company targets healthcare providers in cardiac and thoracic surgery, as well as critical care units, seeking to enhance workflow efficiency and patient safety. Centese is dedicated to reducing healthcare costs and accelerating patient recovery times through intelligent design and reliable clinical data.
How much funding has Centese raised?
Centese has raised a total of $15.3M across 2 funding rounds:
Series B
$15M
Private Equity
$250K
Series B (2023): $15M with participation from MedTech Venture Partners
Private Equity (2026): $250K, investors not publicly disclosed
Key Investors in Centese
MedTech Venture Partners
MedTech Venture Partners is a venture capital firm dedicated to advancing the medical technology sector. They provide crucial financial backing and strategic insights to companies developing innovative healthcare solutions, aiming to foster significant growth and development within the industry.
What's next for Centese?
The recent major strategic investment positions Centese for accelerated growth and market penetration. This capital infusion is expected to fuel further development of their innovative surgical drainage technology and expand their reach within the cardiothoracic and critical care markets. The company's focus on improving patient outcomes and operational efficiency in hospitals suggests a trajectory towards becoming a key player in surgical device innovation, potentially leading to further enterprise-level funding rounds as they scale operations and introduce new product iterations.
See full Centese company page
